So far, so good” was at least one reaction – though not the market’s – to phase I data uncorked by Macrogenics Inc. at the European Society for Medical Oncology meeting in Madrid, where attendees ...
Gilead Sciences Inc. is paying $1.28 billion in cash to acquire Pepstar Therapeutics Ltd.’s oral IL-23 receptor inhibitor program, including lead asset HCXT-2001, to deepen its presence in immunology ...
Fractyl Health Inc. is determined to pursue the development of its Revita system despite its battered share price and looming litigation. It is cutting nearly half of its workforce, discontinuing the ...
It’s been more than four years since the U.S. FTC, at congressional insistence, opened its investigation into pharmacy benefit manager (PBM) practices. The agency needs to wrap it up and release a ...
Worldwide biopharma approvals reached 57 in September, up 50% from August’s 38 and coming in as the second-highest monthly total of the year, behind June’s 64. Through the first three quarters of 2026 ...
Following the close of the sale of its Vega Therapeutics Inc. subsidiary to Incyte Inc. for $1.25 billion up-front in July 2026, Star Therapeutics LLC was left with an astronomical amount of cash for ...
After failing a phase III trial in sepsis-associated kidney injury in 2022, AM-Pharma’s ilofotase alfa has been acquired by Ambrose Healthcare for up to €161 million (US$181 million) and will be taken ...
Japan has backed Nipro Corp.’s Stemirac for full approval, about eight years after the mesenchymal stem cell therapy first ...
The next breakthrough in artificial intelligence-driven drug discovery may depend less on more sophisticated algorithms than ...
Phase III news from competitor Abbvie Inc. in hidradenitis suppurativa (HS) put a sizeable dent in shares of Avalo ...
EQT has signed an agreement to take Qiagen NV private, offering shareholders €46.50 a share in cash, in a deal with an ...
The U.K. is setting up a nationwide randomized, placebo-controlled, double-blind Alzheimer's disease trial, which will test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results